Pharmaceutical company Shire announced that it has been given clearance for its acquisition of ViroPharma Incorporated, a deal previously announced.
Shire announced Friday the expiration of the Hart-Scott-Rodino Act’s merger waiting period, though reports say the deal must meet certain requirements to finalize.
Should the deal go through, however, Shire is set to make the acquisition for about $4.2 billion. The strategic buyout would allow the company to broaden its rare disease treatment portfolio.
Full Content: Zacks
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Ribera Calls for Reform in EU Competition Policies
Dec 10, 2024 by
CPI
DirecTV Urges Second Circuit to Revive Antitrust Lawsuit Against Nexstar
Dec 9, 2024 by
CPI
Omnicom and Interpublic Unite in $13.25B Deal: Big Tech Competition Heats Up
Dec 9, 2024 by
CPI
Federal Ruling Highlights DOJ’s Push Against Algorithmic Collusion in Antitrust Cases
Dec 9, 2024 by
CPI
Judge’s Decision on Kroger-Albertsons Merger Expected Soon
Dec 9, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI
Assessing the Potential for Antitrust Moats and Trenches in the Generative AI Industry
Nov 29, 2024 by
Allison Holt, Sushrut Jain & Ashley Zhou
How SEP Hold-up Can Lead to Entrenchment
Nov 29, 2024 by
Jay Jurata, Elena Kamenir & Christie Boyden
The Role of Moats in Unlocking Economic Growth
Nov 29, 2024 by
CPI
Overcoming Moats and Entrenchment: Disruptive Innovation in Generative AI May Be More Successful than Regulation
Nov 29, 2024 by
Simon Chisholm & Charlie Whitehead